A detailed history of Nuveen Asset Management, LLC transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 275,815 shares of TNYA stock, worth $612,309. This represents 0.0% of its overall portfolio holdings.

Number of Shares
275,815
Previous 275,815 -0.0%
Holding current value
$612,309
Previous $855,000 37.78%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$2.72 - $4.99 $29,892 - $54,840
-10,990 Reduced 3.83%
275,815 $855,000
Q1 2024

May 13, 2024

BUY
$2.88 - $6.8 $374,310 - $883,789
129,969 Added 82.87%
286,805 $1.5 Million
Q4 2023

Feb 14, 2024

BUY
$1.73 - $3.39 $581 - $1,139
336 Added 0.21%
156,836 $508,000
Q3 2023

Nov 14, 2023

SELL
$2.55 - $5.65 $9,753 - $21,611
-3,825 Reduced 2.39%
156,500 $399,000
Q2 2023

Aug 14, 2023

BUY
$2.64 - $7.64 $226,422 - $655,252
85,766 Added 115.03%
160,325 $941,000
Q1 2023

May 15, 2023

BUY
$1.92 - $3.59 $38,536 - $72,054
20,071 Added 36.84%
74,559 $212,000
Q4 2022

Feb 14, 2023

SELL
$1.68 - $3.19 $37,175 - $70,588
-22,128 Reduced 28.88%
54,488 $110,000
Q3 2022

Nov 14, 2022

SELL
$2.9 - $5.88 $348 - $705
-120 Reduced 0.16%
76,616 $222,000
Q2 2022

Aug 15, 2022

BUY
$5.01 - $14.12 $125,234 - $352,957
24,997 Added 48.31%
76,736 $432,000
Q1 2022

May 16, 2022

BUY
$9.41 - $19.3 $197,901 - $405,898
21,031 Added 68.49%
51,739 $564,000
Q4 2021

Feb 14, 2022

BUY
$18.41 - $29.58 $189,125 - $303,875
10,273 Added 50.27%
30,708 $580,000
Q3 2021

Nov 12, 2021

BUY
$15.35 - $26.66 $313,677 - $544,797
20,435 New
20,435 $422,000

Others Institutions Holding TNYA

About Tenaya Therapeutics, Inc.


  • Ticker TNYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,364,700
  • Market Cap $91.8M
  • Description
  • Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...
More about TNYA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.